RAPT Therapeutics (RAPT) Gains from Sales and Divestitures (2021 - 2024)
Historic Gains from Sales and Divestitures for Therapeutics (RAPT) over the last 4 years, with Q3 2024 value amounting to $13500.0.
- Therapeutics' Gains from Sales and Divestitures changed 0.0% to $13500.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $13500.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $13500.0 for FY2023, which is 0.0% changed from last year.
- As of Q3 2024, Therapeutics' Gains from Sales and Divestitures stood at $13500.0, which was down 0.0% from $13500.0 recorded in Q2 2024.
- In the past 5 years, Therapeutics' Gains from Sales and Divestitures registered a high of $14125.0 during Q1 2021, and its lowest value of $13500.0 during Q1 2022.
- In the last 4 years, Therapeutics' Gains from Sales and Divestitures had a median value of $13500.0 in 2022 and averaged $13666.7.
- As far as peak fluctuations go, Therapeutics' Gains from Sales and Divestitures crashed by 442.48% in 2022, and later changed by 0.0% in 2023.
- Quarter analysis of 4 years shows Therapeutics' Gains from Sales and Divestitures stood at $14125.0 in 2021, then fell by 4.42% to $13500.0 in 2022, then changed by 0.0% to $13500.0 in 2023, then changed by 0.0% to $13500.0 in 2024.
- Its Gains from Sales and Divestitures was $13500.0 in Q3 2024, compared to $13500.0 in Q2 2024 and $13500.0 in Q1 2024.